Hwang Ilseon, Song Joon Seon, Cho Eunho, Song Kwon-Ho, Ra Sang Hyun, Choi Chang-Min, Kim Tae Woo, Kim Sung-Han, Kim Jeong Won, Chung Joon-Yong
Department of Pathology, Keimyung University School of Medicine, Dongsan Medical Center Daegu 42601, Republic of Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine Seoul 05505, Republic of Korea.
Am J Cancer Res. 2024 Feb 25;14(2):917-930. doi: 10.62347/TYNU2341. eCollection 2024.
Cyclophilin B (CypB), encoded by peptidylprolyl isomerase B (), is involved in cellular transcriptional regulation, immune responses, chemotaxis, and proliferation. Recent studies have shown that PPIB/CypB is associated with tumor progression and chemoresistance in various cancers. However, the clinicopathologic significance and mechanism of action of PPIB/CypB in non-small cell lung cancer (NSCLC) remain unclear. In this study, we used RNA in situ hybridization to examine PPIB expression in 431 NSCLC tissue microarrays consisting of 295 adenocarcinomas (ADCs) and 136 squamous cell carcinomas (SCCs). Additionally, Ki-67 expression was evaluated using immunohistochemistry. The role of PPIB/CypB was assessed in five human NSCLC cell lines. There was a significant correlation between PPIB/CypB expression and Ki-67 expression in ADC (Spearman correlation =0.374, <0.001) and a weak correlation in SCC (=0.229, =0.007). In ADCs, high PPIB expression (PPIB) was associated with lymph node metastasis (=0.023), advanced disease stage (=0.014), disease recurrence (=0.013), and patient mortality (=0.015). Meanwhile, high Ki-67 expression (Ki-67) was correlated with male sex, smoking history, high pT stage, lymph node metastasis, advanced stage, disease recurrence, and patient mortality in ADC (all <0.001). However, there was no association between either marker or clinicopathological factors, except for old age and PPIB (=0.038) in SCC. Survival analyses revealed that the combined expression of PPIB/Ki-67 was an independent prognosis factor for poor disease-free survival (HR 1.424, 95% CI 1.177-1.723, <0.001) and overall survival (HR 1.266, 95% CI 1.036-1.548, =0.021) in ADC, but not in SCC. Furthermore, PPIB/CypB promoted the proliferation, colony formation, and migration of NSCLC cells. We also observed the oncogenic properties of PPIB/CypB expression in human bronchial epithelial cells. In conclusion, PPIB/CypB contributes to tumor growth in NSCLC, and elevated PPIB/Ki-67 levels are linked to unfavorable survival, especially in ADC.
亲环素B(CypB)由肽基脯氨酰异构酶B()编码,参与细胞转录调控、免疫反应、趋化性和增殖过程。最近的研究表明,PPIB/CypB与多种癌症的肿瘤进展和化疗耐药性相关。然而,PPIB/CypB在非小细胞肺癌(NSCLC)中的临床病理意义及作用机制仍不清楚。在本研究中,我们使用RNA原位杂交技术检测了由295例腺癌(ADC)和136例鳞状细胞癌(SCC)组成的431个NSCLC组织芯片中PPIB的表达情况。此外,采用免疫组织化学方法评估Ki-67的表达。在5种人NSCLC细胞系中评估了PPIB/CypB的作用。在ADC中,PPIB/CypB表达与Ki-67表达之间存在显著相关性(Spearman相关系数=0.374,<0.001),而在SCC中相关性较弱(=0.229,=0.007)。在ADC中,高PPIB表达(PPIB)与淋巴结转移(=0.023)、疾病晚期(=0.014)、疾病复发(=0.013)及患者死亡(=0.015)相关。同时,在ADC中,高Ki-67表达(Ki-67)与男性、吸烟史、高pT分期、淋巴结转移、晚期、疾病复发及患者死亡均相关(均<0.001)。然而,在SCC中,除老年与PPIB(=0.038)外,这两种标志物与临床病理因素均无关联。生存分析显示,PPIB/Ki-67的联合表达是ADC患者无病生存期(HR 1.424,95%CI 1.177 - 1.723,<0.001)和总生存期(HR 1.266,95%CI 1.036 - 1.548,=0.021)不良的独立预后因素,但在SCC中并非如此。此外,PPIB/CypB促进了NSCLC细胞的增殖、集落形成和迁移。我们还观察到PPIB/CypB在人支气管上皮细胞中的致癌特性。总之,PPIB/CypB促进了NSCLC的肿瘤生长,PPIB/Ki-67水平升高与不良生存相关,尤其是在ADC中。